Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12575453 | 0.83 | PTGS2 (0.46) | PTGS2PTGS1HSD11B1KCNH2HTT | |
| SCHEMBL2018913 | 0.82 | TNK2 (0.46) | HTTFYN | |
| SCHEMBL2025519 | 0.78 | HSD11B1 (0.42) | PTGS2PTGS1HSD11B1KCNH2MAOB | |
| SCHEMBL2020736 | 0.76 | MET (0.54) | SMN1; SMN2 | |
| SCHEMBL937686 | 0.74 | TNK2 (0.44) | HTTSMN1; SMN2FYN | |
| SCHEMBL1676176 | 0.73 | PTGS2 (0.63) | PTGS2PTGS1HTTSMN1; SMN2BCL2L1 | |
| SCHEMBL7359540 | 0.71 | SOS1 (0.64) | PTGS2PTGS1HTTSMN1; SMN2 | |
| SCHEMBL8941654 | 0.70 | PTGS2 (0.56) | PTGS2PTGS1HTTSMN1; SMN2 | |
| SCHEMBL937271 | 0.70 | HPGD (0.48) | PTGS2KCNH2HTTSMN1; SMN2 | |
| SCHEMBL2016682 | 0.68 | GRM5 (0.46) | SMN1; SMN2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343977-B2 | Substituted triazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343977-B2 | Substituted triazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343977-B2 | Substituted triazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2011082271-A2 | SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | TYMP, TK1, DPYD | PTGS2 1375/4885PTGS1 1087/4885HSD11B1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.